The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Now a test that offers new precision in prostate cancer detection
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Roche says the move marks a step forward in its digital transformation strategy
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Subscribe To Our Newsletter & Stay Updated
